CD38 and Miyoshi myopathy: The past two decades have significantly refashioned the therapeutic options of MM, such as the availability of proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), histone deacetylase inhibitors (HDACi), anti-CD38 monoclonal antibodies (mABs), antibody-drug conjugates (ADC), and selective inhibitors nuclear export (SINE) (6).